Key facts
- This page summarizes Norman David Eansor's Form 4 filing for BIO-TECHNE Corp (TECH).
- 14 reported transactions and 15 derivative rows are listed below.
- Accepted by SEC: 16 Nov 2021, 15:51.
Norman David Eansor - 12 Nov 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)
- Reporting relationship
- President-Protein Sciences
- Issuer ticker
- TECH
- Reported as of
- 12 Nov 2021
- Net transaction value
- -$10,192,045
- SEC form
- 4
- Accepted by SEC
- 16 Nov 2021, 15:51:43 UTC
- Prior SEC filing
- 02 Sep 2021
- Next SEC filing
- 26 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Nick as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Norman David Eansor filed Form 4 for BIO-TECHNE Corp (TECH) on 16 Nov 2021.
Change
- Previous filing in this sequence was filed on 02 Sep 2021.
- Current net transaction value: -$10,192,045.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TECH
transaction
Common Stock
Options Exercise
- Transaction value
- $3,396,233
- Shares
- +27,159
- Change %
- +2061%
- Price
- $125.05
- Shares after
- 28,477
- Date
- 12 Nov 2021
- Ownership
- Direct
TECH
transaction
Common Stock
Sale
- Transaction value
- $352,860
- Shares
- -700
- Change %
- -2.5%
- Price
- $504.09
- Shares after
- 27,777
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
TECH
transaction
Common Stock
Sale
- Transaction value
- $100,956
- Shares
- -200
- Change %
- -0.72%
- Price
- $504.78
- Shares after
- 27,577
- Date
- 12 Nov 2021
- Ownership
- Direct
TECH
transaction
Common Stock
Sale
- Transaction value
- $150,897
- Shares
- -300
- Change %
- -1.1%
- Price
- $502.99
- Shares after
- 27,277
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F2
TECH
transaction
Common Stock
Sale
- Transaction value
- $270,725
- Shares
- -537
- Change %
- -2%
- Price
- $504.14
- Shares after
- 26,740
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F3
TECH
transaction
Common Stock
Sale
- Transaction value
- $202,002
- Shares
- -400
- Change %
- -1.5%
- Price
- $505.00
- Shares after
- 26,340
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F4
TECH
transaction
Common Stock
Sale
- Transaction value
- $2,038,221
- Shares
- -4,054
- Change %
- -15%
- Price
- $502.77
- Shares after
- 22,286
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F5
TECH
transaction
Common Stock
Sale
- Transaction value
- $4,554,137
- Shares
- -9,043
- Change %
- -41%
- Price
- $503.61
- Shares after
- 13,243
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F6
TECH
transaction
Common Stock
Sale
- Transaction value
- $4,533,985
- Shares
- -8,989
- Change %
- -68%
- Price
- $504.39
- Shares after
- 4,254
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F7
TECH
transaction
Common Stock
Sale
- Transaction value
- $1,281,407
- Shares
- -2,535
- Change %
- -60%
- Price
- $505.49
- Shares after
- 1,719
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F8
TECH
transaction
Common Stock
Sale
- Transaction value
- $203,002
- Shares
- -401
- Change %
- -23%
- Price
- $506.24
- Shares after
- 1,318
- Date
- 12 Nov 2021
- Ownership
- Direct
- Footnotes
- F9
TECH
transaction
Common Stock
Options Exercise
- Transaction value
- $99,915
- Shares
- +799
- Change %
- +61%
- Price
- $125.05
- Shares after
- 2,117
- Date
- 16 Nov 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TECH
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -27,159
- Change %
- -97%
- Price
- $0.000000
- Shares after
- 799
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,159
- Exercise price
- $125.05
- Footnotes
- F11
TECH
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -799
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 799
- Exercise price
- $125.05
- Footnotes
- F11
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,550
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,550
- Exercise price
- $177.32
- Footnotes
- F11
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,066
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,066
- Exercise price
- $177.32
- Footnotes
- F12
TECH
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,151
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,151
- Exercise price
- Footnotes
- F10, F13
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,948
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,948
- Exercise price
- $190.41
- Footnotes
- F13
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 21,265
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,265
- Exercise price
- $190.41
- Footnotes
- F14
TECH
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,575
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,575
- Exercise price
- Footnotes
- F10, F15
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,488
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,488
- Exercise price
- $267.87
- Footnotes
- F15
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,318
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,318
- Exercise price
- $267.87
- Footnotes
- F16
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,975
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,975
- Exercise price
- $267.87
- Footnotes
- F17
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,975
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,975
- Exercise price
- $267.87
- Footnotes
- F18
TECH
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,556
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,556
- Exercise price
- Footnotes
- F10, F19
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,080
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,080
- Exercise price
- $481.82
- Footnotes
- F19
TECH
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,107
- Date
- 12 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,107
- Exercise price
- $481.82
- Footnotes
- F20
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 20 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F10
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Footnote F11
Fully exercisable.
Footnote F12
Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
Footnote F13
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Footnote F14
Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
Footnote F15
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Footnote F16
Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
Footnote F17
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
Footnote F18
Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
Footnote F19
Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Footnote F20
Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.